Heska Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska or view top-rated stocks.

Wall Street analysts have given Heska a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heska wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Heska is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Heska.

Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Tuesday, August, 3rd. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.13. The medical research company had revenue of $64.93 million for the quarter, compared to analysts' expectations of $56.82 million. Heska had a negative net margin of 0.59% and a positive trailing twelve-month return on equity of 1.42%. The company's revenue for the quarter was up 42.0% compared to the same quarter last year.
View Heska's earnings history.

Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSKA shares have increased by 218.8% and is now trading at $260.86.
View which stocks have been most impacted by COVID-19.

Heska issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250 million-$260 million, compared to the consensus revenue estimate of $245.24 million.

5 Wall Street analysts have issued 12-month target prices for Heska's shares. Their forecasts range from $195.00 to $310.00. On average, they anticipate Heska's share price to reach $263.00 in the next year. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for Heska or view top-rated stocks among Wall Street analysts.

5 employees have rated Heska CEO Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Heska include Ipsen (IPSEY), Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Lantheus (LNTH), Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Aspira Women's Health (AWH), OncoCyte (OCX), Lucira Health (LHDX), Quotient (QTNT), MyMD Pharmaceuticals (MYMD) and VolitionRx (VNRX).
View all of HSKA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Heska's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (16.58%), Vanguard Group Inc. (6.11%), State Street Corp (3.15%), Wells Fargo & Company MN (2.36%), Invesco Ltd. (2.27%) and Dimensional Fund Advisors LP (2.19%). Company insiders that own Heska stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends for Heska.

HSKA stock was sold by a variety of institutional investors in the last quarter, including abrdn plc, Millennium Management LLC, Renaissance Technologies LLC, Monarch Partners Asset Management LLC, Russell Investments Group Ltd., FMR LLC, JPMorgan Chase & Co., and Tudor Investment Corp Et Al. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski, and Sharon J Larson.
View insider buying and selling activity for Heska or view top insider-selling stocks.

HSKA stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Invesco Ltd., BlackRock Inc., Goldman Sachs Group Inc., State Street Corp, Axiom Investors LLC DE, Nuveen Asset Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Heska or or view top insider-buying stocks.

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSKA stock can currently be purchased for approximately $260.86.

Heska has a market capitalization of $2.78 billion and generates $197.32 million in revenue each year. The medical research company earns $-14,400,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

Heska employs 602 workers across the globe.

The official website for Heska is www.heska.com.

Heska is headquartered at 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538.

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at (970) 493-7272 or via email at [email protected]